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Abstract
Background: P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) play a critical role in keeping
neurotoxic substances from entering the brain. We and others have previously reported an impact of inflammation
on the regulation of adult blood–brain barrier (BBB) efflux transporters. However, studies in children have not been
done. From the pediatric clinical perspective, it is important to understand how the central nervous system (CNS)
and BBB drug efflux transporters differ in childhood from those of adults under normal and inflammatory
conditions. Therefore, we examined and compared the regulation of P-gp and BCRP expression and transport
activity in young and adult BBB and investigated the molecular mechanisms underlying inflammatory responses.
Methods: Rats at postnatal day (P) P21 and P84, corresponding to the juvenile and adult stages of human brain
maturation, respectively, were treated with endothelin-1 (ET-1) given by the intracerebroventricular (icv) route.
Twenty-four hours later, we measured P-gp and BCRP protein expression in isolated brain capillary by
immunoblotting as well as by transport activity in vivo by measuring the unbound drug partitioning coefficient of
the brain (Kp,uu,brain) of known efflux transporter substrates administered intravenously. Glial activation was
measured by immunohistochemistry. The release of cytokines/chemokines (interleukins-1α, 1-β (IL-1β), -6 (IL-6), -10
(IL-10), monocyte chemoattractant protein (MCP-1/CCL2), fractalkine and tissue inhibitor of metalloproteinases-1
(TIMP-1)) were simultaneously measured in brain and serum samples using the Agilent Technology cytokine microarray.
Results: We found that juvenile and adult BBBs exhibited similar P-gp and BCRP transport activities in the normal
physiological conditions. However, long-term exposure of the juvenile brain to low-dose of ET-1 did not change BBB
P-gp transport activity but tended to decrease BCRP transport activity in the juvenile brain, while a significant increase
of the activity of both transporters was evidenced at the BBB in the adult brain. Moreover, juvenile and adult brain
showed differences in their expression profiles of cytokines and chemokines mediated by ET-1.
Conclusions: BBB transporter activity during neuroinflammation differs between the juvenile and adult brains. These
findings emphasize the importance of considering differential P-gp and BCRP transport regulation mechanisms
between adult and juvenile BBB in the context of neuroinflammation.
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Background
The blood–brain barrier (BBB) maintains brain homeosta-
sis and limits the entry of toxins and pathogens into the
brain. Adenosine triphosphate-binding cassette (ABC)
transporters play a critical role in keeping neurotoxic sub-
stances from entering the brain and in transporting toxic
metabolites out of the brain [1,2]. These transporters are
largely responsible for the multidrug resistance (MDR)
phenomenon, which plays a crucial role in treatment
failure for several brain diseases such as seizure [3] and
human immunodeficiency (HIV-1) infection disease [4,5].
In response to injury or brain diseases [6], the central
nervous system (CNS) exhibits inflammatory features,
which have effects on the expression and function of BBB
efflux transporters in adults [7-9]. Because intricate devel-
opmental processes are taking place during the prenatal
and postnatal periods, we hypothesized that BBB efflux
transporters might also undergo important changes during
brain maturation, and might possibly have age-related dif-
ferences in the inflammatory response. There is now a
wealth of evidence that age could have a significant effect
on response to cytokines, which, in turn, could modulate
BBB efflux transporters expression and activity [10-13] in
an age-dependent manner.
Endothelin-1 (ET-1), an arterial vasoconstrictive and
vasodilator peptide cytokine [14], is released in several
CNS disorders [15-25]. Members of the endothelin fam-
ily are released by various cell types in brain, including
endothelial cells and some glial cells, especially during
inflammation [26-29]. In effect, ET-1 is known to be a
component of the brain’s innate immune response. It is
released during the activation of the brain’s innate im-
mune response [19-31] triggered by a variety of stimuli,
including infection, trauma, disease, and cell stress and
characterized mainly by glial activation and the release
of proinflammatory cytokines and chemokines [32-36].
Previous works in our laboratory as well as studies from
other laboratories have shown that proinflammatory
cytokines such as TNFα and IL1β cause a release of ET-
1 at the BBB level [28-35]. In turn, ET-1 causes the re-
lease of other cytokines and chemokines such as MCP-1
[36] thus amplifying the inflammatory signals. ET-1
released in this inflammatory context is known to regu-
late the P-gp activity. Indeed, long-term exposure of iso-
lated rat brain capillaries to the pro-inflammatory
cytokine TNFα caused release of ET-1 and then an in-
crease of P-gp transport activity [31,37]. As inflamma-
tion occurs in nearly all CNS disorders [8], it is
important to understand how it alters the function of
drug efflux transporters since these alterations will affect
the efficacy of CNS drugs [37]. However, in vivo studies
of the impact of ET-1 on the regulation of P-gp and
other brain-to-blood ABC transporters such as breast
cancer resistance protein (BCRP) in adults and more
particularly in children have not been done. From
the clinical perspective of developing new drugs with
enhanced efficacy in the CNS of children, it is important
to understand how the BBB drug efflux transporters are
regulated under inflammatory conditions in children’s
brains specifically. That is the main target of the present
study. We examined and compared regulation of P-gp and
BCRP expression and transport activity in young and adult
BBB and investigated the molecular mechanisms under-
lying these processes. To evaluate whether potential devel-
opmental differences in neuroinflammatory responses
could contribute to the age-specific patterns of BBB efflux
transporter expression, rats at postnatal day (P) P21 and
P84, corresponding to the juvenile and adult stages of
human brain maturation, respectively, were treated with
ET-1 by intracerebroventricular (icv) route. Twenty-four
hours after ET-1 icv administration, we measured P-gp
and BCRP protein expression in isolated brain capillary by
immunoblotting, and we assessed their transport activity
in vivo by measuring the unbound brain/plasma concen-
tration ratios (Kp,uu, brain) of known efflux transporter sub-
strates [38,39] administered intravenously. The findings
are discussed in the context of glial activation leading to
differential release of cytokines/chemokines, in particular
interleukins-1α, 1-β (IL-1β), -6 (IL-6), -10 (IL-10), mono-
cyte chemoattractant protein (MCP-1/CCL2), fractalkine,
and tissue inhibitor of metalloproteinases-1 (TIMP-1).
These inflammatory mediators were measured in the brain
and serum of rats treated with ET-1 at two stages of brain
maturation: P21 (pediatric stage in humans) and P84
(adult stage in humans).
Methods
Experimental design
Male Wistar rats at two stages of brain maturation were
used in our experiments: Postnatal (P) P21, corresponding
to the pediatric stage in human; and P84, corresponding
to the adult stage in human. The experimental design was
articulated in the following steps: 1) Verification of ven-
tricular stereotaxic coordinates in both juvenile and adult
rats; methylene blue was injected intracerebroventricularly
in order to visualize the stereotaxic implantation of the in-
jection cannulae and the injection site into the brain lat-
eral ventricles. 2) BBB integrity assessment by the Evan’s
Blue test, the baclofen test, and the measure of mRNA
relative expression of a tight-junction component, zonula
occludens-1 (ZO-1); ET-1 was administered intracerebro-
ventricularly. Twenty-two hours later, a solution of 3%
Evan’s Blue dissolved in 0.9% saline was administered
intravenously (4 ml/kg). Two hours later, brains were iso-
lated and the BBB integrity was assessed by verifying the
absence of blue trace and by albumin immunohistochem-
ical (IHC) detection in the cortex and the hippocampus.
BBB integrity was further assessed by measuring (using
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real-time PCR) mRNA relative expression of the ZO-1 in
brain microvessels isolated 24 h after ET-1 treatment. 3)
Measure of P-gp and BCRP protein expression in brain
microvessels isolated 24 h after ET-1 icv injection. 4)
Measure of P-gp and BCRP protein activity in vivo 24 h
after ET-1 icv injection; Twenty hours after ET-1 icv treat-
ment, P-gp and BCRP substrates were administered intra-
venously during four hours (steady state (ss) achievement)
at a concentration of 1 mg/kg/h. At the end of the infusion
period, blood was sampled, brain was isolated and the
administered substrates were quantified in the two com-
partments using mass spectrometry. P-gp and BCRP
transport activity was estimated by the ratio between sub-
strates unbound brain concentrations (C) and unbound
plasma concentrations. This ratio is described by the un-
bound partitioning coefficient,
Kp;uu;brain ¼ Csstot;brainx fu;brain=Csstot;plasmax fuplasma:
5) Immunohistochemistry of glial fibrillary acidic protein
(GFAP), a glial activation marker [40], in cortex and
hippocampus of rat brains isolated 24 h after ET-1 treat-
ment. 6) Brain and serum cytokines/chemokines quantifi-
cation 24 h after ET-1 icv injection. The design of our
research methodology is illustrated in Scheme 1.
Reagents
Bovine serum albumin (BSA), N-alpha-tosyl-L-lysinyl-
chloromethylketone (TLCK) and (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) were from Sigma
(Saint Louis, MO, USA). Hank's buffered salt solution
(HBSS), phosphate buffered saline (PBS) and penicillin-
streptomycin-neomycin (PSN) were from Invitrogen
(Carlsbad, CA, USA). Collagenase/dispase and DNase I
was from Roche (Indianapolis, IN, USA). The NP-40
reagent (IGEPAL; CA-630) was from Sigma-Aldrich
(St-Quentin-Fallavier, France). Primary antibodies from
Santa Cruz Biotechnologies (Santa Cruz, CA, USA)
were: anti-MDR1 (sc-55510), anti-BCRP (sc-130933).
Anti-actin (Mab 1501) was from Millipore (Molsheim,
France). The secondary antibodies: goat anti-rabbit, goat
anti-mouse and mouse anti-goat IgGs conjugated to
Scheme 1 An illustration of the experimental design. 1. Verification of intracerebroventricular (icv) stereotaxic coordinates. 2. Blood–brain
barrier (BBB) integrity assessment. 3. P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) expression measurement. 4. P-gp and BCRP
transport activity measurement. 5. Glial activation evaluation by glial fibrillary acid protein (GFAP) immunohistochemistry. 6. Brain and serum
cytokines/chemokines quantification.
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horseradish peroxidase (HRP) were from Santa Cruz
Biotechnologies.
Digoxin (CAS 20830-75-5) and prazosin (CAS 19237-
84-4) were from Sigma-Aldrich (St-Quentin-Fallavier,
France). Internal standards vinblastine (CAS 143-67-9) and
chlorpropamide (CAS 94-20-2) were from Sigma-Aldrich
(Saint-Quentin-Fallavier, France). ET-1 was from Bachem
(Heidelberg, Germany).
Animals
Rats were from Janvier Laboratories (Le Genest St Isle,
France). Two groups of male Wistar rats [postnatal days
21 and 84] corresponding to the juvenile and adult stages
of BBB maturation, respectively were used. Rats were
maintained in a temperature and humidity controlled
(19 C-23°C) room under a 12:12 h light–dark cycle, and
were fed a standard diet (rodent rat chow) ad libitum with
free access to tap water. Animal use in this research was
approved in accordance with the Declaration of Helsinki,
the European community’s council directives (86/609/
EEC, November 24, 1986) and the French directives con-
cerning the use of laboratory animals.
Stereotaxic injections
Rat of different ages were weighed using a digital scale.
All animals were then anesthetized with ketamine
(87 mg/kg)/xylazine (13 mg/kg) and placed in a rodent
stereotaxic apparatus. Skin and cranial fascia were
resected and the skull exposed. A injection cannulae
(from Cortat SA, Courrendlin, Switzerland) (length
25 mm, outer diameter 0.28 mm, internal diameter
0.18 mm) was inserted into the right lateral cerebral
ventricle (4 mm ventral to the dura) via a hole that was
drilled in the cranium at 1.08 mm posterior and 2 or
1.5 mm lateral to the bregma for P21 or P84 rats, re-
spectively. The tip of a Hamilton syringe needle was
briefly lowered to a depth of 3.8 or 4.2 mm for P21 or
P84 rats, respectively, and immediately raised by 0.2 mm
to create a trough. Each rat, received a double injection
of ET-1 at a dose of 25 pmol/kg, or a vehicle control
((saline solution (0.9% NaCl)). The needle was left in for
5 minutes following the end of the injection, after which
it was raised slowly, craniotomies were filled with gel-
foam, and the scalp was sutured with wound clips. The
wound was closed with self-dissolving sutures and
swabbed with iodine. For pain control, lidocaine solution
was applied. Animals were placed in a heated recovery
cage, where they remained until the end of the study.
Twenty-four hours after intracerebroventricular (icv) in-
jection, animals were used for the assessment of un-
bound brain/plasma concentration of efflux drug
substrates (see below) and/or euthanized by anesthetic
injection and decapitated. Serum and brains were col-
lected and frozen for further investigations.
Assessment of blood–brain barrier integrity
The integrity of the BBB was assessed by assessing the
brain uptake of Evans blue dye and by following the ex-
pression of tight junctions on the brain microvessels. For
that, ET-1 was administered icv. Twenty-two hours later,
a solution of 3% Evans Blue dissolved in 0.9% saline was
administered intravenously (iv, 4 ml/kg). Evans blue
binds to serum albumin, giving rise to a high molecular
complex which remains in intravascular spaces and dif-
fuses to the extravascular space with BBB disruption
[41]. Two hours after Evans blue iv administration,
brains were isolated and the BBB integrity was assessed
by verifying the absence of blue trace and by albumin
IHC detection in the cortex and the hippocampus. BBB
integrity was further assessed by measuring (using real-
time PCR) mRNA relative expression of a tight-junction
component, the ZO-1, in brain microvessels isolated
24 h after ET-1 treatment.
Isolation of brain microvessels
Rat brain microvessels were isolated as described previ-
ously [42]. The purity of collected brain microvessels
was checked after RNA isolation and RT- PCR experi-
ments by measuring the expression of cell-specific mar-
ker genes using specific primer for brain endothelial
cells (CD31 or PECAM), for astrocytes (glial fibrillary
acid protein or GFAP) and for pericytes (α-actin) as pre-
viously described [42].
To further evaluate changes in BBB integrity, the mRNA
expression profile of the tight junction zonula occludens-1
(ZO-1) was assessed as described previously [5,42]. Quan-
titative expression of tight junction components was
determined using 0.4 μM of cDNA for each primer set in
the RT2 Pathway-Focused ProfilerTM Array from SABios-
ciences (TJ: catalog CAPR09279) (Frederick, Maryland,
USA) according to the manufacturer’s recommended
protocol. The specific amplification conditions were 2 min-
utes at 50°C, 10 minutes at 95°C followed by 40 amplifica-
tion cycles at 95°C for 0.5 minute and 60°C for 1 minute
to reinitialize the cycle again. The specificity of each reac-
tion was also assessed by melting curve analysis to ensure
the presence of only one product. Relative gene expression
values were calculated as 2-ΔCT, where ΔCT is the differ-
ence between the amplification curve (CT) values for
genes of interest and the housekeeping gene (hypoxan-
thine-guaninephosphoribosyltransferase, HPRT; glyceral-
dehyde phosphate dehydrogenase, GAPDH). If the CT
was higher than 35, we considered the expression level too
low to be applicable.
Western blot analysis
To analyze expression at the protein level, western blot
analysis was performed on rat cerebral microvessels as
reported elsewhere [31,37]. Optical density was quantified
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using VersaDoc analysis software (BioRad Laboratories,
Hercules, CA).
GFAP immunohistochemistry
Rats were anesthetized with isoflurane and subjected to
intra-cardiac perfusion with 0.1% phosphate buffered sa-
line (PBS). The brains were quickly removed and fixed
in 4% paraformaldehyde (PFA) for 4 days, incubated in
30% sucrose solution, frozen in isopentane at −50°C, and
stored at −80°C. Using a cryostat microtome, 40 μm
sagittal brain slices were obtained and stored at −20°C in
cryoprotectant solution until processing as free-floating
sections. Brain slices were incubated in 30% H2O2 for
20 minutes before addition of normal goat serum block-
ing solution. Sections were incubated overnight (12 h) at
4°C with the primary antibody anti-GFAP (rabbit anti-
body, Abcam ab7260, 1/5000) (Paris, France) then for
30 minutes with the secondary biotinylated antibody
(anti-rabbit IgG, ABC kit Abcam ab8627, 1/200). Sec-
tions were incubated with an avidine biotine solution
(ABC kit Abcam ab 8627) for 30 minutes, and staining
was revealed after 8-minute incubation with 3,3’-diami-
nobenzidine tetrahydrochloride (Sigma), 30% H2O2. Sec-
tions were washed in PBS to stop the reaction.
GFAP image analysis was performed using Visilog 6.8
imaging software (Noesis, France), by measuring the per-
centage of stained surface over a manually defined area
(optical density), excluding the interface of adjacent tis-
sues (10× and 40× objectives). GFAP was assessed in the
cortex and hippocampus.
Brain and serum cytokines/chemokines quantification
Protein extraction from brain tissue
Brain samples were weighed and homogenized with a
Precellys 24 tissue homogenizer (Bertin Technologies,
Montigny-le-Bretonneux, France) in 2 ml tubes contain-
ing 1.4 mm of ceramic beads (Cat 03961-1-003, Bertin
Technologies). Then 500 μL of lysis buffer (20 mM
TrisHCl pH 7.4, 0.15 M NaCl, 2 mM EDTA, 1 mM
EGTA with protease inhibitor cocktail (Santa Cruz Bio-
techologies, sc-29131)) was added to each tube. Samples
were centrifuged (100 g) for 10 minutes at 4°C, and then
the supernatant was removed and centrifuged a second
time (20,000 g for 40 minutes at 4°C) to remove any
remaining debris. Protein levels for all samples were
quantified by the Bradford method and stored at −80°C.
Measurement of cytokines and chemokines in serum
and brain supernatants All cytokines, IL-1α, IL-1β, IL-
6, IL-10, MCP-1/ccl2, fractalkine, and TIMP-1were simul-
taneously measured in brain and serum samples using the
Agilent technology cytokine microarray (Tebu-bio, Le
Perray-en-Yvelines, France). Data were calculated by gen-
erating a calibration curb obtained using reconstituted
cytokine standard in matrix of serum and buffer for brain
samples. After incubation of samples with antibody cock-
tail and specific wash steps (as per manufacturer), 80 μL
of Cy3 equivalent dye-conjugated streptavidin was added
to each sample before incubation overnight at 4°C. The
signals were visualized with a high-resolution microarray
scanner (Agilent Technologies, Cat G2505B). Data extrac-
tion was done with the microarray analysis software Gene-
Pix 6.0. Quantitative data analysis was done with
QuantibodyW Q-Analyzer software (RayBiotech, Norcross,
GA). All brain values were corrected for individual serum
measurements as follows and described previously [6].
Brain cytokine pg=mgð Þ ¼ Brain cytokine pg=mgð Þ
 Serum cytokine pg=mgð Þ½
∗0:02% correction factorð Þ
Assessment of unbound brain/plasma concentration ratio
(Kp,uu,brain) of known efflux transporter substrates
A time-course distribution study of drug in plasma and
brain of rats treated or not by pharmacological agents
was conducted as previously described [42]. Substrates
of specific efflux transporters (digoxin (P-gp substrate)
and prazosin (BCRP substrate)) were infused via the
femoral vein for 4 h, a time sufficient to achieve steady
state, at a concentration of 1 mg/kg/h. Six rats per treat-
ment were used. At the end of the infusion period, blood
was sampled from the abdominal aorta in Eppendorf
tubes (Eppendorf, Le Pecq, France) containing a sodium
heparinate evaporated solution at 1000 U/ml, and then
centrifuged for 5 minutes at 3000 g at 4°C to collect
plasma. After blood collection, brains were collected and
weighed. Plasma samples and brains were stored at −20°C,
for subsequent bioanalysis by mass spectrometry.
Transporter substrate quantification in biological samples
Brains were mixed with ultrapure water (2 ml/g of brain)
using an Ultraturrax T65 system (IKA-Werke, Staufen,
Germany) Extract suspensions (200 μL) were submitted
to protein precipitation with 1 ml of methanol previ-
ously spiked with internal standard (1 μg/ml). After
evaporation of the methanolic extracts to dryness, the
dried extracts were resuspended in 500 μL of 1%
NH4OH. Plasma (200 μL) was diluted with 200 μL of 1%
NH4OH. Both brain extracts and diluted plasmas were
submitted to solid–liquid extraction (SPE) on Oasis car-
tridges (reference 186000366 (Waters, Saint Quentin,
France) as previously described [36]. The eluates (2 ×
250 μL) of 2% formic acid in methanol and 2 × 250 μL
of acetonitrile/methanol (1/1, v/v)) were evaporated
to dryness, reconstituted in 100 μL of 10 mM ammo-
nium acetate/acetonitrile/formic acid, 95/5/0.1 v/v and
20 μL was injected into the chromatographic system.
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Chromatography was performed using a Waters
Acquity UPLC system on a BEH Shield RP18 column
(2.1 mm × 100 mm, 1.7 μm) coupled with a BEH Shield
RP18 1.7 μm Van Guard™ Pre-Column (Waters, Saint-
Quentin-en-Yvelines, France). Mobile phase solvent A
comprised 0.1% formic acid in 10 mM ammonium acet-
ate, and mobile phase solvent B comprised 0.1% formic
acid in acetonitrile. The run time was 5 minutes, and
analytes were eluted with the following gradient: from 0
to 1 minute 5% solvent B, from 1 to 2.5 minutes the pro-
portion of solvent B increased linearly from 5 to 80%,
from 2.5 to 3 minutes a steady state of 80% solvent B
was maintained, and from 3.1 to 5.0 minutes there was
re-equilibration of initial conditions. The flow rate was
set at 0.6 ml/min, the column temperature was main-
tained at 60°C and the autosampler at 4°C. The detec-
tion was performed with triple quadrupole mass
spectrometer Quattro Premier XE monitored by Mas-
sLynx software, version 4.1 (Waters, Saint-Quentin-en-
Yvelines, France) equipped with an electrospray
ionization source operating alternatively in positive and
negative mode. Tuning parameters were: capillary voltage
3 kV, source temperature 120°C, and desolvation
temperature 350°C. The multiple reaction monitoring tran-
sitions for analytes were as follows: m/z digoxin 325.2
>779.4 and m/z prazosine 384.1 >247.2.
Analytes were quantified by means of calibration
curves using vinblastine or chlorpropamide as the in-
ternal standard.
For plasma assay, calibration ranges were from 1.0 to
200 ng/ml for digoxin and from 0.4 to 170 ng/ml for
prazosine. For brain extract assay, calibration ranges
were from 1.0 to 100 ng/ml for digoxin and from 0.5 to
100 ng/ml for prazosine.
Measurement of the unbound partitioning coefficient of the
drugs
The ratio between brain concentrations and plasma con-
centrations to estimate the delivery of drug to the brain
was calculated [39,43]. This ratio can be described by
the partition coefficient, Kp:
Kp;brain ¼ Csstot;brain=Csstot;plasma
where CSStot is the steady-state drug concentration for
total (bound and unbound) in brain and plasma.
Taking into account protein binding in plasma and brain
tissue components of efflux/influx transporter substrates
(digoxin and prazosin) measured using equilibrium dialy-
sis in triplicate for each compound as described elsewhere
(Table 1) [39], the unbound partitioning coefficient Kp,uu
which determined the net influx and efflux of drug across
the BBB, was calculated as follows:
Kp;uu;brain ¼ Csstot;brainxfu;brain=Csstot;plasmaxfupplasma
where fu,plasma and fu,brain is the fraction of unbound drug
(Table 1) in plasma and brain tissue, respectively.
Statistical analysis
Statistical analysis was performed using the Prism 3.0
program (GraphPad Software, Inc, San Diego, CA) and
the R statistical software (R Development Core Team,
2009). Comparisons between groups were performed
using one-way analysis of variance (ANOVA) with the
Student-Bonferroni-post test and the unpaired Student’s
t test. Data are presented as mean ± S.E.M. Statistical
significance was set at P <0.05.
Results
Blood–brain barrier integrity assessment after
intracerebroventricular injection of endothelin-1 in rats
An intact BBB simplifies the assessment of BBB-efflux
transporter activity. We used Evans blue to determine
whether ET-1 in our experimental conditions altered
BBB integrity in juvenile or adult rats. Results depicted
in Figure 1 demonstrate that in control animals as well
as in ET-1-treated animals no albumin labeling or blue
trace was detected in the cortex or in the hippocampus.
These results showed no change in BBB permeability.
Moreover, there was also no change in the quantitative
real-time PCR analysis of ZO-1 mRNA from freshly iso-
lated rat brain microvessels after ET-1 treatment. To-
gether, these results suggest that ET-1 under the
conditions of these experiments does not change BBB
permeability.
Comparison of P-glycoprotein and breast cancer resistance
protein expression in juvenile and adult brain microvessels
during brain inflammation mediated by endothelin-1
Previous in vitro results suggest that short-term expos-
ure of adult rat brain endothelial cells to ET-1 decreases
P-glycoprotein [31], whereas longer-term exposure
(24 h) of adult human brain endothelial cells causes no
changes in P-glycoprotein expression [7]. We found here
that ET-1 administration into brain did not alter P-gp
(Figure 2) or BCRP (Figure 3) expression in adult or in
juvenile brain microvessels isolated twenty-four hours
after ET-1 administration, as revealed by western blot.
Table 1 Digoxin and prazosin unbound protein fraction
in plasma (fu,plasma) and brain tissue (fu,brain)
Compounds fu,plasma fu,brain fu,brain/fu,plasma ratio
Prazosin 0.204 ± 0.001 0.071 ± 0.004 0.349
Digoxin 0.379 ± 0.001 0.218 ± 0.027 0.576
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Figure 1 (See legend on next page.)
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Comparison of transporter activity in juvenile and adult
blood–brain barrier during brain inflammation mediated
by endothelin-1
To determine whether there were differential responses
to ET-1 in transporter activity of P-gp and BCRP in the
juvenile and adult BBBs, the unbound brain and un-
bound plasma concentration ratios (Kp,uu,brain) for known
substrates of P-gp (digoxin) and BCRP (prazosin) were
determined 24 h after ET-1 icv injection. In the un-
treated state, there were no differences between juveniles
and adults for P-gp (Figure 4) or BCRP (Figure 5) activ-
ity. However, ET-1 used to trigger neuroinflammatory
reactions characterized by cytokines/chemokines secre-
tion, caused different regulation of P-gp and BCRP
transport activity (Figures 4 and 5) between juvenile and
adult rats. Notably, ET-1 induced an enhanced trans-
porter activity of P-gp as assessed by digoxin efflux from
brain [Kp,uu,brain = 0.04 ± 0.006, for treated adult rat ver-
sus Kp,uu,brain 0.07 ± 0.01, P <0 .05), whereas no signifi-
cant change occurred in P-gp activity at the juvenile
BBB (Figure 4). The decrease of brain uptake in the ET-
1-treated adult animals strikingly coincided with the
increases in the unbound plasma concentration of di-
goxin compared with the control (67.84 ± 22.74 ng/ml
versus 47.75 ± 10.30 ng/ml), whereas no significant
change in the plasma concentration of digoxin compared
with the control was observed in juvenile rats (36.76 ±
6.50 ng/ml versus 47.75 ± 6.79 ng/ml). ET-1 also
enhanced efflux of prazosin, the substrate for BCRP, at
the adult BBB [Kp,uu,brain = 0,09 ± 0.01 , for treated adult
rat versus Kp,uu,brain 0.23 ± 0.02, P <0.0001)], with a cor-
responding arithmetic increase in unbound plasma con-
centration (10.06 ± 2.03 versus 7.40 ± 0.90 ng/ml)
(Figure 5). Conversely, at the juvenile BBB, 24 h after
ET-1 treatment, efflux of prazosin tend to decrease [Kp,
uu,brain = 0.30 ± 0.07, for treated adult rat versus Kp,uu,
brain 0.19 ± 0.05, for animal controls (P = 0.11)]. This ten-
dency to decrease in BCRP activity at the juvenile BBB
was strikingly associated with decreased unbound
plasma prazosin concentration (4.60 ± 1.52 ng/ml versus
8.56 ± 1.75 ng/ml, P <0 .05) (Figure 5).
Comparative glial activation between juvenile and adult
rat brain cortex and hippocampus under inflammation
mediated by endothelin-1
We determined whether the activation of glial cells by
ET-1 in juvenile and adult rat brains could be respon-
sible for the differential effects of ET-1 on efflux trans-
porter activity. Immunohistochemistry depicted in
Figure 2 Expression of P-glycoprotein in freshly isolated rat
brain microvessels after endothelin-1 treatment of juvenile and
adult rats. Rats equivalent to pediatric (P21) and adult (P84) human
brain were used. Twenty-four hours after intracerebroventricular (icv)
injection of endothelin-1 (ET-1) was used to trigger inflammatory
reactions, brain microvessels were isolated, and P-glycoprotein
expression was assessed by western blot as reported in Methods.
Results show no difference in P-glycoprotein expression after ET-1
treatment. Immunoblot represents mean ± S.E.M from three batches
of brain endothelial microvessels. Statistical comparisons: *P <0.05,
**P <0.01 and ***P <0.0001.
(See figure on previous page.)
Figure 1 Representative immunohistochemical staining of albumin in the adult and juvenile brains (scale bars, 5 μm). A) Stereotaxic
implantation of the cannulae was checked using intracerebroventricular (ICV) methylene blue-injected rats which permitted visualization of the
stereotaxic implantation of the injection cannulae and the injection site into the brain lateral ventricles. Cannula implantation reached the lateral
ventricle as shown by the blue color and cannula scare (blood trace) (as referred to in Paxinos and Watson’s stereotaxic atlas). Moreover,
methylene blue diffused to the hippocampus. B) Blood–brain barrier (BBB) permeability after endothelin-1 (ET-1) injection was assessed using
albumin immunohistochemical (IHC) in IV Evans blue injected rats. ET-1 was administered intracerebroventricularly. Twenty-two hours later a
solution of 3% Evans Blue dissolved in 0.9% saline was administered intravenously (4 ml/kg). No albumin labeling or blue trace was detected in
the cortex or in the hippocampus of adult or juvenile rat brains, suggesting a lack of BBB breakdown after icv injection of ET-1. C) BBB
permeability after ET-1 injection was also assessed by measuring (using real-time PCR) mRNA relative expression of a tight-junction component,
the ZO-1 gene, in brain microvessels isolated 24 h after ET-1 treatment. Results represent mean ± S.E.M from three batches of brain endothelial
microvessels. Statistical comparisons: *P <0.05, **P <0.01 and ***P <0.0001.
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Figure 6 shows that ET-1 induced activation of glial cells
as measured by GFAP. In cortex, ET-1 increased GFAP
in glial cells in adults (1.94-fold,) as well as in juvenile
brain (1.78-fold, P <0.0001). However, variance analysis
(one-way ANOVA) with Bonferroni’s multiple compari-
son post test showed difference in the basal glial activation
between juvenile and adult brain cortex (P = 0.0467). In
the hippocampus, the basal glial activation is statistically
different between juvenile and adult (P = 0.0013), but ET-1
enhanced GFAP expression in glial cells of adult brain
2-fold and in juvenile brain 1.62-fold (Figure 6).
Cytokine and chemokine responses mediated by
endothelin-1 in juvenile and adult brains
Cytokines and chemokines were measured in brain and
serum 24 h after ET-1 injection (25 pmol/kg). Protein
expression of cytokines and chemokines in the brain was
calculated taking into account that 0.02% of the analyte
serum value for serum is predicted to contribute to the
value for the brain [6]. Expression patterns of all cyto-
kines and chemokines are depicted in Figure 7 for
juvenile and adult rat brain, respectively. Among the
panel of cytokines and chemokines tested, only IL-10,
IL-6, CCL2/MCP-1, IL-1α, IL-1β, fractalkine, and TIMP-
1 were detected. Cytokines that remained significantly
elevated in adult brain were IL-10, Il-1β, IL6, Ccl2/
MCP1 and TIMP-1. Adult and juvenile rat brains
showed different patterns for fractalkine, TIMP-1, IL-10,
Il-1β, and Ccl2/MCP-1. The expression of fractalkine,
IL-10 and TIMP-1 was significantly decreased in juvenile
brain, but increased in adult brain. In addition, we noted
a striking difference in the magnitude of Il-1β, at basal
level and after ET-1 administration [3.23-fold increase
(P <0.001) versus 1.22 (P <0.01) fold increase), and of
IL-6 [3.46-fold increase (P <0.05) versus 1.34-fold in-
crease] secretion between adult and juvenile brain. IL-1α
showed the same pattern in juvenile and adult brain.
Discussion
CNS pharmacotherapy is impeded by the existence ‘CNS
barriers’ at the interface between blood and neural tis-
sue. As a result, many drugs fail as therapeutic agents
for the CNS because they are pumped out of the brain.
To overcome these drug efflux transporters, recent re-
search in the field aims at identifying the factors and the
intracellular signaling mechanisms implicated in their
regulation in order to modulate their activity and im-
prove pharmacotherapy of brain diseases. For years, BBB
efflux transporters have been studied in the adult organ-
ism. But, there is a wide-spread belief among pediatri-
cians, neurologists, and neuroscientists that the BBB in
the embryo, fetus, newborn, and infant is ‘immature’, im-
plying caution in giving drugs to infants [44]. Moreover,
intricate developmental processes are taking place dur-
ing the prenatal and postnatal periods, which might
mean that BBB efflux transporters could also undergo
important changes during brain maturation, and might
possibly have age-related differences in the inflammatory
response. There is growing evidence suggesting that the
immune system, through systemic or cerebral inflamma-
tion, disturbs the BBB efflux transporters [45], and these
alterations can affect the efficacy of CNS-acting drugs.
However, current knowledge on the functional status
of the BBB in immature organism remains very limited.
Thus, from the clinical perspective of developing new
drugs with enhanced efficacy in both the adult and chil-
dren CNS, it is important to understand 1) the role of
the BBB drug efflux transporters in the CNS at the dif-
ferent stages of brain maturation and 2) the mechanisms
that regulate their functional activity, under both normal
and inflammatory conditions.
In this study, we evaluated the impact of acute cere-
bral inflammation mediated by ET-1 on BBB efflux
transporters with a comparison between juvenile and
adult rats. Specifically, we evaluated, ex vivo and in vivo,
Figure 3 Expression of breast cancer resistance protein (BCRP)
in freshly isolated rat brain microvessels after endothelin-1
treatment of juvenile and adult rats. Rats equivalent to pediatric
(P21) and adult (P84) human brain were used. Twenty-four hours
after intracerebroventricular (icv) injection of endothelin-1 (ET-1) was
used to trigger inflammatory reactions, brain microvessels were
isolated, and BCRP expression was assessed by western blot as
reported in Methods. Results show no difference in BCRP expression
after ET-1 treatment. Immunoblot represents mean ± S.E.M from
three batches of brain endothelial microvessels. Statistical
comparisons: *P <0.05, **P <0.01 and ***P <0.0001.
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the impact of intracerebroventricular (icv) injection of
ET-1, on the expression and activity of two of the most
clinically relevant BBB drug efflux transporters, the P-gp
and the BCRP transporters.
Our results showed that, under inflammatory condi-
tions, BBB drug efflux transporters are regulated differ-
ently in juvenile rats when compared to adult rats, and
that this differential regulation may be due, in part, to a
maturational difference in glial basal levels, and neuro-
inflammatory response triggered by ET-1.
Since inflammation has been reported to influence
BBB integrity [27,28], we first investigated in our experi-
mental conditions whether icv injection of ET-1 changed
BBB permeability. BBB permeability was evaluated by
assessing the brain uptake of Evans blue dye to ensure
the functionality of the BBB to macromolecule entry
after ET-1 treatment, and by following the expression of
tight junctions on the brain microvessels to evaluate the
integrity of tight junctions which restrict paracellular
movement to small molecules across the BBB. Results
depicted in Figure 1 demonstrate a lack of BBB perme-
ability changes with the use of Evan blue as well as the
use of baclofen, as small molecule which does not cross
the BBB (data not shown). In addition, we found no
modification in the ZO-1 gene expression during the
cerebral inflammation triggered by ET-1 treatment, and
Figure 4 P-glycoprotein activity regulation at the blood–brain barrier through activation of endothelin-1 signaling. Twenty-hours after
endothelin-1 (ET-1) intracerebroventricular (icv) treatment, digoxin, a P-glycoprotein (P-gp) substrate, was administered intravenously in adult
brain (A) and juvenile brain (B) during four hours (steady state (ss) achievement) at a concentration of 1 mg/kg/h. At the end of the infusion
period, blood was sampled, brain was isolated and the administered substrate was quantified using mass spectrometry. P-gp transport activity
was estimated by the ratio between the substrates’ unbound brain concentrations and unbound plasma concentrations. Unbound plasma
digoxin concentration in adult (C) and juvenile rat (D) was also calculated. ET-1 induces an enhanced transporter activity of P-gp at the adult
blood–brain barrier (BBB), whereas no significant change occurred in P-gp activity at the juvenile BBB. Data represent the mean concentration for
five rat brains/plasma. Variability is given by bars ± S.E.M. Data were analyzed using Student’s t-test. Statistical comparisons: *P <0.05.
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this in both juvenile and adult brains. These findings
allowed us to determine the impact of neuroinflamma-
tion on the expression and transport activity of BCRP
and P-gp in adult and juvenile brains at the BBB. We
first compared P-gp and BCRP transport activity be-
tween juvenile and adult BBB, and found that juvenile
and adult BBB have the same P-gp and BCRP transport
activity (Additional file 1). We also found evidence that
the transport activities of P-gp and BCRP are enhanced
by icv ET-1 at the adult BBB, whereas no significant
modulation of P-gp transport activity and a tendency to
decrease in BCRP transport activity were seen at the ju-
venile BBB (Figures 4 and 5). Thus, these results gave
evidence that P-gp and BCRP transporters at the BBB
level are regulated differently under pathological condi-
tions in juvenile brain when compared to adult. These
findings emphasize the importance of considering differ-
ential P-gp and BCRP transporter regulation mechan-
isms between juvenile and adult BBB in the context of
pathological conditions.
Second, after assessing BBB transport activity in adult
and juvenile brains in the context of ET-1 treatment, we
aimed at understanding the underlying mechanisms be-
hind this differential regulation. We suspected a role of
neuroinflammatory response triggered by ET-1 because
it is likely that cytokine secretion in adult and juvenile
brains controls the regulation of BBB transporters [9]. In
the brain, the inflammatory response begins with recruit-
ment of the innate immune system. Rapidly, in response to
infection or injury, microglia, major inflammatory cells of
the monocyte/microphage lineage that reside in the brain,
are activated [46]. Microglia are important phagocytic cells,
Figure 5 BCRP activity regulation at the blood–brain barrier through activation of endothelin-1 signaling. Twenty-hours after endothelin-
1 (ET-1) intracerebroventricular (icv) treatment, prazosin, a BCRP substrate, was administered intravenously in adult brain (A) and juvenile brain (B)
during four hours (steady state (ss) achievement) at a concentration of 1 mg/kg/h. At the end of the infusion period, blood was sampled, brain
was isolated and the administered substrate was quantified using mass spectrometry. BCRP transport activity was estimated by the ratio between
unbound prazosin brain concentrations and unbound plasma prazosin concentrations. Unbound plasma prazosin concentration in adult (C) and
juvenile rat (D). Data represent the mean concentration for three or five rat brains/plasma. Variability is given by bars ± S.E.M. Data were analyzed
using Student’s t-test. Statistical comparisons: *P <0.05.
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and once activated they release numerous inflammatory
molecules, particularly pro and anti-inflammatory cytokines
and chemokines [47] (Proinflammatory molecules such as
tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β),
interleukin-6 (IL-6) [48-50], chemokines (IL-8, MIP-1α,
MIP-1β, MCP-1) [51,52], proteases [53], and anti-
inflammatory molecules such as TGF-β and IL-10 [54]).
Later, astrocytes are activated [55]. Apart from being
involved in a variety of physiologic processes, astrocytes
rapidly react to different neurological insults. Upon activa-
tion, a series of changes occur in astrocytes, leading to the
acquisition of macrophage differentiation markers and ef-
fector properties. One main feature of these changes is the
increase in the number and size of glial fibrillary acidic pro-
tein (GFAP) expressing cells. GFAP is an intermediate fila-
ment cytoskeletal protein expressed primarily by astrocytes
and it is considered as the marker of astrocytes [40]. Con-
comitant with GFAP overexpression, astrocytes release
many proinflammatory mediators and upregulate the ex-
pression of several inflammatory molecules, contributing to
the amplification of inflammation [34]. These facts allow us
in this study, to test whether the inflammatory response
triggered by ET-1 can be responsible for the differential
regulation of P-gp and BCRP transporters between juve-
niles and adults. For that, we quantified 1) the glial activa-
tion marker, the GFAP in hippocampus and cortex of rat
brains treated with ET-1, and 2) a panel of cytokines and
chemokines that could be induced by ET-1 in both juvenile
and adult rat brains. We found a difference in the GFAP
basal levels between the two populations either in hypo-
campus or in the brain cortex, but our results showed a
pronounced glial activation in adult and juvenile cortex
and hippocampus coincided with cytokine/chemokine
levels (Figures 6 and 7). Our findings were that IL6, IL-1β,
CCl2/MCP-1, TIMP-1 and IL-10 increased significantly in
adult brain compared with juvenile brain. These results
emphasize the fact that brain development such as glial
maturation is likely of paramount importance in the syn-
thesis of specific cytokines such as IL6 for example. Indeed,
IL6 is a well-known marker of glial activation [56] and the
autocrine action of this interleukin on glial cells might ac-
count for an increase of ABC transporters at the cell sur-
face. This increase is important in the secretion of ccl2/
MCP-1 by astrocytes upon toll-like receptor 3 activation as
reported recently [57]. Thus, a differential GFAP basal level
and a differential secretion of cytokines might lead to a dif-
ferential regulation of ABC transporters at the BBB level.
Moreover, taking into account the differential effect of ET-1
on cytokine levels in juvenile and adult brains, we suggest
that the increased levels of cytokines in the adult brain and
more particularly IL-6 and IL-1β may cause functional but
not transcriptional regulation of P-gp and BCRP in adult
BBB. Indeed, there was no modulation of protein synthesis
in BCRP and P-gp in adult rat brain microvessels (Figure 5).
Figure 6 Effect of endothelin-1 on glial activation in adult and juvenile brains. Representative immunohistochemical staining of glial
fibrillary acidic protein (GFAP) in the juvenile (A) and adult (C) brains cortex and quantitative analysis of GFAP expression (E). Comparisons
between groups were performed using one-way analysis of variance (ANOVA) with Bonferroni post test. Data are presented as mean ± S.E.M.
Statistical significance was set at P <0.05. Each bar is expressed as the mean ± S.E.M; ***P <0 .0001 compared with control group. (D)
Representative immunohistochemical staining of GFAP in the juvenile brain and adult (F) hippocampus and quantitative analysis of GFAP
expression (E). Each bar is expressed as the mean ± S.E.M; ***P <0.0001 compared with control group.
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Modulation of transport activity for P-gp in response to
peripheral pain inflammation with no increase in its protein
expression has been previously reported [58]. We found no
published results addressing whether cerebral inflammation
as mediated by ET-1 regulates either P-gp or BCRP activity
at the adult or juvenile BBB. Based on our results and the
literature, we suggest that cytokine synthesis in the adult
brain modulates BCRP and P-gp activity at the BBB by
post-translational mechanisms such as phosphorylation and
cellular localization of transporters. Inflammation regulates
a number of intracellular signal transduction pathways
[59-61] involved in the regulation of transporter activity. At
the BBB, P-gp has been localized to plasma membrane sur-
faces as well as several subcellular sites, and there is over-
whelming evidence suggesting that the localization of P-gp
and its trafficking within brain endothelial cells contributes
to its function [62,63]. To formally demonstrate that cyto-
kine synthesis is a cause of the differential regulation of
transporter activity between juvenile and adult BBB, we
increased the amount of ET-1 administered after determin-
ing the lack of BBB breakdown. At the dose of 125 pmol/kg
of ET-1, the juvenile brain exhibited increases in IL1β,
MCP-1, and IL6 ( Additional file 2). Despite the level of
those cytokines in the brain, the juvenile BBB showed a de-
crease in BCRP activity which strikingly coincided with the
decrease of unbound plasma prazosin concentration (3.77
± 1.58 ng/ml versus 8.56 ± 3.77 ng/ml, P <0.05). In addition,
the increase in the administered dose of ET-1 did not
change the activity of P-gp in the juvenile BBB. We
observed no significant decrease of digoxin concentration
in unbound plasma of juvenile animals (23.50 ± 7.58 treated
animals versus 47.88 ± 6.80 for control animals, P <0.05). In
adult brain, BBB at the dose of 125 pmol/kg of ET-1 (data
not shown) showed the same profile regarding the increase
of P-gp and BCRP activity compared with the dose of
25 pmol/kg. These findings suggest the involvement of
other parameters in the differential regulation of P-gp and
BCRP at the BBB, particularly in juvenile brain. Thus, fur-
ther investigation is warranted to define more precisely the
underlying mechanisms. It has been reported that the tran-
scriptional activity of ABC transporters is under the control
of orphan nuclear receptors such as steroid and xenobiotic
receptors, and that their expression and function are regu-
lated by environmental stimuli that induce stress. Recent
studies show that increased transporter expression occurs
in response to signals that activate specific transcription
factors including, PXR, CAR, NF-κB and AP-1, and
reduced transporter activity occurs rapidly and reversibly in
response to signaling through Src kinase, protein kinase C
and estrogen receptors [8]. Moreover, Bauer and colleagues
have shown in rat brain capillaries that tumor necrosis fac-
tor alpha (TNF-α) binding to its receptor TNFR1 leads to
the release of ET-1 which in turn acts through its receptor
ETB to continue the signaling cascade via nitric oxide syn-
thase (NOS) and protein kinase C (PKC) [31]. This long-
term exposure leads to an increase of P-gp activity [31]
which is in agreement with our results regarding the adult
brain but not the juvenile brain even at low dose of ET-1
(25 pmol/kg) or at the dose of 125 pmol/kg. Thus, to deter-
mine the underlying mechanisms behind the differential
regulation of the BBB P-gp and BCRP transporter further
studies are required and these must be primarily focused
on the role of these multiple signaling pathways modulating
the expression and activity of ABC transporters at the BBB
level in children compared to adults. In addition, difference
in the ontogenesis of ET-1 receptor (ETA) evidenced (data
not shown) in our laboratory at the level of BBB in juvenile
and adult brain might be also taken into account to explain
this differential functional regulation of P-gp and BCRP
transporter.
Conclusions
In the present study, we found that BBB transporter ac-
tivity during neuroinflammation is not affected in the
same manner in juvenile brain as it is in the adult brain.
This is the first report that illustrates the differential
regulation of BBB transporter activity in pediatric and
adult brains. In the pediatric brain long-term exposure
to ET-1 leads to no modulation of BBB Pgp transport ac-
tivity and BCRP transport activity tends to decrease
while a significant increase of both transporters activity
was evidenced in the adult brain. Further studies such
as microglial activation, ontogenesis of endothelin
receptors (ETB, ETA), NFkβΙ, ΙΙ, PKC isoforms, NOS,
sphingolipid signaling pathways in the context of brain
inflammation are warranted to understand accurately
and precisely the differential regulation of BBB-ABC
transporters in pediatric and adult brains. In this con-
text, we suggest that potential selective reduction of
transcriptional factors such as PKC and NOS isoform in
the brain cortex could decrease BBB BCRP transport
activity and lead to enhancement of CNS drug
(See figure on previous page.)
Figure 7 Cytokines and chemokines levels for 24 hours in juveniles (P21) and adult (P84) rat brains after a single intracerebral
injection of endothelin-1. All cytokines, IL-1α, IL-1β, IL-6, IL-10, MCP-1/ccl2, fractalkine and TIMP-1 were simultaneously measured in brain and
serum samples using the Agilent technology cytokine microarray (Tebu-bio). All brain values were corrected for individual serum measurements
as described previously [6]. Comparisons between groups were performed using one-way analysis of variance (ANOVA) with the Student-
Bonferroni post test. Data are presented as mean ± S.E.M. Statistical significance was set at P <0.05. Graph plotted as mean ± S.E.M. *P <0.05, **P
<0.01, ***P < 0.0001 compared with animal controls. The number of animal tested: n = 3 or 5 rats for each group.
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pharmacotherapy in pediatric brain. Our study gives the
evidence of age-related differences in the regulation of
drug efflux transporters under inflammatory conditions,
and emphasizes the importance of taking into account
the specific properties of the juvenile BBB and distin-
guishing it from the adult one in the clinical perspective
of developing new drugs with enhanced efficacy in chil-
dren’s CNS. Subsequently, it is highly important to de-
termine the pathways modulating the activity of drug
efflux transporters under pathological conditions, both
in children and adult brains, because targeting these
pathways may open new therapeutic avenues to improve
drug delivery into the brain.
Additional files
Additional file 1: Age-related changes in P-gp, and bcrp function at
the BBB. Rats at pediatric (P21) and adult (P84) stages of
braindevelopment were used. The in vivo plasma and brain exposure of
tested efflux transporter substrates [digoxin (P-gp substrate): 0.5 mg/kg h,,
and prasozin (bcrp substrate): 0.25 mg/kg h] was assessed using
unanesthetized rats catheterized in the femoral vein. Drug infusion was
performed for a period of 4 h (steady state), and then the unbound
partitioning coefficient brain/plasma concentration ratio (Kpuu, brain) for
each tested efflux transporter substrate was determined as described in
the Experimental Section. Data represent the mean concentration for 3 or
5 rat brains and 3 or 5 plasmas; variability is given by bars ± SEM.
Statistical comparisons: *P < 0.05, **P < 0.01, and ***P < 0.0001.
Additional file 2: Cytokines and chemokines levels in juvenile brain
after a single intracerebral injection of endothelin-1 for 24 h at the
dose of 125 pmol/kg. All cytokines, IL-1 β, IL-6, IL-10, MCP-1/ccl2,
fractalkine, TIMP-1, IL-13, cinculin (CINC-1) were simultaneously measured
in brain and serum samples using the Agilent technology cytokine
microarray (Tebu bio). All brain values were corrected for individual
serum measurements as follows and described previously [6]: Graph
plotted as mean ± S.E.M. *P <.05, **P <0.01, ***P <0.001 compared with
animal controls with n = 3 or 5 rats for each group.
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